Alan Bilsland

7.0k citations

37 papers · 1.0k · h-index 21

Impact in

Physiology top 5%
- Telomeres, Telomerase, and Senescence
Biotechnology top 5%
- Cancer Research and Treatments

Papers in

Molecular Biology 23
- RNA Interference and Gene Delivery 9
- Advanced biosensing and bioanalysis techniques 6
- CRISPR and Genetic Engineering 4
- Genomics and Chromatin Dynamics 3
Physiology 18
- Telomeres, Telomerase, and Senescence 18

Co-authors: W. Nicol Keith (25 shared papers)Marta Bon (2 shared papers)T.R. Jeffry Evans (5 shared papers)Jiangqin Zhao (5 shared papers)Claire J. Cairney (10 shared papers)Justin Bower (4 shared papers)Rosalind Glasspool (3 shared papers)Stacey F. Hoare (5 shared papers)
Journals: Neoplasia (5 papers)Cancer Research (4 papers)Oncogene (4 papers)Journal of Clinical Oncology (1 paper)Journal of Mammary Gland Biology and Neoplasia (1 paper)
Partner nations: United Kingdom United States Germany

In The Last Decade

Alan Bilsland

37 papers receiving 991 citations

Peers

Replace Anandhkumar Raju with:

Anandhkumar Raju Singapore

A. M. Burger United States

Ekaterina Bassett United States

Dawid Walerych Poland

Guikai Wu United States

Jaroslav Žák United States

Yuebo Gan United States

MV Blagosklonny United States

Zeng‐Fu Shang China

Sylvia Musto United States

Alan Bilsland relative to Anandhkumar Raju Singapore Anandhkumar Raju's profile →

Citations per field

00.5×2×3.2×

Anandhkumar Raju · 1×

×2.8 381/136

PHYSI

×2.2 123/56

BIOTE

×2.0 22/11

AGING

×1.0 647/668

MB

×3.2 177/55

GENET

Citations per year

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

'26

Countries citing papers authored by Alan Bilsland

Since Specialization

Citations

This map shows the geographic impact of Alan Bilsland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Bilsland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Bilsland more than expected).

Fields of papers citing papers by Alan Bilsland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Bilsland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Bilsland. The network helps show where Alan Bilsland may publish in the future.

Co-authors

The 25 scholars most cited alongside Alan Bilsland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alan Bilsland Line = papers co-authored together Alan Bilsland links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Synthetic Anticancer Gene Medicine Exploits Intrinsic Antitumor Activity of Cationic Vector to Cure Established Tumors Cancer Research ·Christine Dufès, W. Nicol Keith, Alan Bilsland, Irina Proutski, Ijeoma F. Uchegbu, Andreas G. Schätzlein	2005	98
2	Fragment‐based drug discovery—the importance of high‐quality molecule libraries Molecular Oncology ·Marta Bon, Alan Bilsland, Justin Bower, Kirsten McAulay	2022	96
3	Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954 Oncogene ·Jane A. Plumb, Alan Bilsland, Rania Kakani, Jiangqin Zhao, Rosalind Glasspool, Richard J. Knox, T.R. Jeffry Evans, W. Nicol Keith	2001	82
4	Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms Oncogene ·Claire J Anderson, S F Hoare, Margaret Ashcroft, Alan Bilsland, W. Nicol Keith	2005	74
5	Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase Oncogene ·Alan Bilsland, Claire J Anderson, Aileen J. Fletcher‐Monaghan, Fiona McGregor, T.R. Jeffry Evans, Ian Ganly, Richard J. Knox, Jane A. Plumb, W. Nicol Keith	2003	64
6	A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT Oncogene ·Kyle Lafferty‐Whyte, Claire J. Cairney, Malcolm Will, Nedime Serakıncı, (unknown), Nadia Zaffaroni, Alan Bilsland, W. Nicol Keith	2009	51
7	Cancer cell senescence: a new frontier in drug development Drug Discovery Today ·Claire J. Cairney, Alan Bilsland, T.R. Jeffry Evans, Jon Roffey, Dorothy C. Bennett, Masashi Narita, C Torrance, W. Nicol Keith	2012	44
8	Activation of Telomerase RNA Gene Promoter Activity by NF-Y, Sp1, and the Retinoblastoma Protein and Repression by Sp3 Neoplasia ·Jiangqin Zhao, Rosalind Glasspool, Stacey F. Hoare, Alan Bilsland, István Szatmári, W. Nicol Keith	2000	41
9	Telomerase-directed molecular therapeutics Expert Reviews in Molecular Medicine ·W. Nicol Keith, Alan Bilsland, T.R. Jeffry Evans, Rosalind Glasspool	2002	35
10	Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies Nature Clinical Practice Oncology ·W. Nicol Keith, Alan Bilsland, Maryon Hardie, TR Jeffry Evans	2004	32
11	Transcriptional Repression of Telomerase RNA Gene Expression by c-Jun-NH2-Kinase and Sp1/Sp3 Cancer Research ·Alan Bilsland, Katrina H. Stevenson, Stuart P. Atkinson, Walter Kölch, W. Nicol Keith	2006	29
12	Dynamic Telomerase Gene Suppression via Network Effects of GSK3 Inhibition PLoS ONE ·Alan Bilsland, Stacey F. Hoare, Katrina H. Stevenson, Jane A. Plumb, Natividad Gomez-Roman, Claire J. Cairney, Sharon Burns, Kyle Lafferty‐Whyte, Jon Roffey, Tim Hammonds, W. Nicol Keith	2009	29
13	Modulation of Telomerase Promoter Tumor Selectivity in the Context of Oncolytic Adenoviruses Cancer Research ·Alan Bilsland, Andrew Merron, Georges Vassaux, W. Nicol Keith	2007	28
14	Involvement of NF‐Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene FEBS Letters ·Jiangqin Zhao, Alan Bilsland, Stacey F. Hoare, W. Nicol Keith	2003	28
15	A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria PubMed ·W. Nicol Keith, Tom Vulliamy, Jiangqin Zhao, Muhlis Cem Ar, Can Erzık, Alan Bilsland, Birsen Ülkü, Anna Marrone, Philip J. Mason, Monica Bessler, Nedime Serakıncı, Inderjeet Dokal	2004	28
16	Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery Pharmaceuticals ·Kirsten McAulay, Alan Bilsland, Marta Bon	2022	28
17	MicroRNA and Senescence: The Senectome, Integration and Distributed Control Critical Reviews™ in Oncogenesis ·Alan Bilsland, John Revie, W. Nicol Keith	2013	25
18	Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma BMC Genomics ·Kyle Lafferty‐Whyte, Alan Bilsland, Claire J. Cairney, Lorna Hanley, Nigel B. Jamieson, Nadia Zaffaroni, Karin Oien, Sharon Burns, Jon Roffey, Susan M. Boyd, W. Nicol Keith	2010	24
19	TCEAL7 Inhibition of c-Myc Activity in Alternative Lengthening of Telomeres Regulates hTERT Expression Neoplasia ·Kyle Lafferty‐Whyte, Alan Bilsland, Stacey F. Hoare, Sharon Burns, Nadia Zaffaroni, Claire J. Cairney, (unknown)	2010	22
20	Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives Journal of Cellular and Molecular Medicine ·Alan Bilsland, Claire J. Cairney, W. Nicol Keith	2010	22

About Alan Bilsland

Alan Bilsland is a scholar working on Molecular Biology, Physiology, Genetics, Biotechnology and Cancer Research, having authored 37 papers that have together received 1.0k indexed citations. Recurring topics across this work include Telomeres, Telomerase, and Senescence (18 papers), RNA Interference and Gene Delivery (9 papers), Advanced biosensing and bioanalysis techniques (6 papers), Virus-based gene therapy research (5 papers), Cancer Research and Treatments (4 papers), CRISPR and Genetic Engineering (4 papers), Click Chemistry and Applications (3 papers) and Genomics and Chromatin Dynamics (3 papers). The work is most often cited by research in Physiology (381 citations), Biotechnology (123 citations), Aging (22 citations), Molecular Biology (647 citations) and Genetics (177 citations). Alan Bilsland has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include W. Nicol Keith, Marta Bon, T.R. Jeffry Evans, Jiangqin Zhao, Claire J. Cairney, Justin Bower, Rosalind Glasspool, Stacey F. Hoare, Jane A. Plumb and Richard J. Knox. Their work appears in journals such as Neoplasia, Cancer Research, Oncogene, Journal of Clinical Oncology and Journal of Mammary Gland Biology and Neoplasia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Alan Bilsland

Impact in

Papers in i

In The Last Decade

Alan Bilsland

Peers

Countries citing papers authored by Alan Bilsland

Fields of papers citing papers by Alan Bilsland

All Works

About Alan Bilsland

Explore authors with similar magnitude of impact

Papers in